Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT)

ADM Tronics Unlimited (OTCMKTS:ADMT) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ADM Tronics Unlimited and Atossa Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADM Tronics Unlimited	0	0	0	0	0.00
Atossa Genetics	2	0	2	1	2.40

Atossa Genetics has a consensus price target of $6.33, suggesting a potential upside of 886.35%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than ADM Tronics Unlimited.

Earnings and Valuation

This table compares ADM Tronics Unlimited and Atossa Genetics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADM Tronics Unlimited	$3.20 million	2.28	-$120,000.00	N/A	N/A
Atossa Genetics	N/A	N/A	-$25.50 million	($0.24)	-2.68

ADM Tronics Unlimited has higher revenue and earnings than Atossa Genetics.

Insider and Institutional Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. 73.0% of ADM Tronics Unlimited shares are owned by company insiders. Comparatively, 9.5% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ADM Tronics Unlimited and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADM Tronics Unlimited	-3.87%	-15.66%	-5.89%
Atossa Genetics	N/A	-49.42%	-44.76%

Volatility & Risk

ADM Tronics Unlimited has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Summary

Atossa Genetics beats ADM Tronics Unlimited on 7 of the 12 factors compared between the two stocks.

About ADM Tronics Unlimited

ADM Tronics Unlimited, Inc., through its subsidiaries, develops, manufactures, and sells electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. It operates through Chemical, Electronics, and Engineering segments. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. In addition, the company provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. Further, it offers water-based, adhesive and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Additionally, the company provides research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products, as well as medical electronic therapeutic technology. ADM Tronics Unlimited, Inc. was incorporated in 1969 and is headquartered in Northvale, New Jersey.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.